Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.

Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW.

Gastroenterology. 2010 Sep;139(3):797-805, 805.e1. doi: 10.1053/j.gastro.2010.06.005. Epub 2010 Jun 9.

2.

Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.

Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W.

J Natl Cancer Inst. 1998 Aug 19;90(16):1212-8.

3.

Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.

Meyskens FL Jr, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, Alberts DS, Gerner EW.

J Natl Cancer Inst. 1994 Aug 3;86(15):1122-30.

PMID:
8028034
4.

Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL.

Cancer Causes Control. 2012 Oct;23(10):1739-44. doi: 10.1007/s10552-012-0051-6. Epub 2012 Aug 21.

5.

Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.

Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL.

Br J Cancer. 2013 Feb 19;108(3):512-8. doi: 10.1038/bjc.2013.15. Epub 2013 Jan 22.

6.

DFMO: targeted risk reduction therapy for colorectal neoplasia.

Laukaitis CM, Gerner EW.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):495-506. doi: 10.1016/j.bpg.2011.09.007. Review.

7.

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL.

Cancer Prev Res (Phila). 2009 Mar;2(3):209-12. doi: 10.1158/1940-6207.CAPR-08-0203. Epub 2009 Mar 3.

8.

A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.

Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, Verma AK.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):989-92.

9.

Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.

Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B.

Cancer Prev Res (Phila). 2011 Jul;4(7):1052-60. doi: 10.1158/1940-6207.CAPR-11-0067. Epub 2011 Apr 4.

10.

Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.

Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW.

Gastroenterology. 2004 Feb;126(2):425-31.

11.

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW.

Cancer Prev Res (Phila). 2008 Jun;1(1):32-8. doi: 10.1158/1940-6207.CAPR-08-0042.

13.

Regulation of transglutaminase activity by polyamines in the gastrointestinal mucosa of rats.

Wang JY, Viar MJ, Johnson LR.

Proc Soc Exp Biol Med. 1994 Jan;205(1):20-8.

PMID:
7906881
14.

Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps.

Chow HH, Earnest DL, Clark D, Mason-Liddil N, Kramer CB, Einspahr JG, Guillen-Rodriguez JM, Roe DJ, Malone W, Crowell JA, Alberts DS.

Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):351-6.

16.

Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia.

Sinicrope FA, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, Lewin J, Morlan B, Hong WK.

Cancer Prev Res (Phila). 2011 Jun;4(6):829-39. doi: 10.1158/1940-6207.CAPR-10-0243.

17.

Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Roy UK, Stringer DE, Blohm-Mangone KA, Padilla-Torres JL, Guillen-R JM, Gerner EW.

Nutr Cancer. 2006;56(2):172-81.

18.

Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial.

Calaluce R, Earnest DL, Heddens D, Einspahr JG, Roe D, Bogert CL, Marshall JR, Alberts DS.

Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1287-92.

19.

Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.

Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA, Pomplun M, Tutsch KD.

Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):907-12.

20.

Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine.

Boyle JO, Meyskens FL Jr, Garewal HS, Gerner EW.

Cancer Epidemiol Biomarkers Prev. 1992 Jan-Feb;1(2):131-5.

Items per page

Supplemental Content

Write to the Help Desk